SKS Technique Clinical Case

Slides:



Advertisements
Similar presentations
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
Advertisements

LAD/D1 bifurcation lesion. Crush technique. 35yr old male.
Bifurcation LAD/D2 lesion. Provisional T stenting.
J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.
Bifurcation stenting. Crush technique. LAD / Diagonal 68 yr old male
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
One patient, two years, three choices, four PCI ZHAO Peng Cardiology , the Affiliated Hospital of Medical College of CPAPF, Tianjin, China.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Featuring Bifurcation Trans-Radial Approach Technical Issues Martial Hamon Caen, France Provisionnal T stenting With the Frontier stent Main Branch Balloon.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The FRONTIER Stent Registry: Safety and Feasibility.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Disrupt CAD Study Design
Adel Gamal, MD and Mohamed Saber, Msc
Ospedale San Raffaele, Milan, Italy
Nightmares in the Cath Lab
Will we ever see a dedicated bifurcated DES in clinical practice?
Bifurcation PCI: Basic Techniques and Data from Clinical Trials
Interesting Case Presentation
BRANCH Bare Metal BifuRcAtion SteNt Clinical Trial in Humans Early Clinical Experience by Raoul Bonan, MD On behalf of the BRANCH study investigators.
(DES)+BVS +DCB for long diffuse LAD disease
Strategy planning in coronary bifurcation stenting
Intra-Aortic Balloon Pump For Complex Calcified Left-Main Bifurcation Lesion Supawat Ratanapo, MD Medical College of Georgia, Augusta University.
The Tryton Bifurcation Trial:
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
BVS Expand: First Results of Wide Clinical Applications
Late stent thrombosis Ashish shah, Tim Kinnaird, W J Penny
The XIENCE V EXCEED Study
Subintimal Tracking and Reentry for CTO STAR Method
On behalf of J. Belardi, M. Leon, L. Mauri,
Stenting of Coronary Arteries in Non Stress/Benestent Disease
TAXUS II and IV: two-year follow-up
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
REALITY: 8 month results
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Kyoto University Hospital, Japan
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
Presented at ACC 2003 Late Breaking Clinical Trials
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Main branch restenosis at 1 year
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
ENDEAVOR II Five-Year Clinical Follow-up
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Long Term Clinical Results from the Endeavor Program: 5-Year Follow up
Maintenance of Long-Term Clinical Benefit with
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
A simple practical technique to protect the side branch during PCI for coronary bifurcation lesions: Side branch balloon submerged embedding technique 
MACE: Death, MI or TLR at 5 years
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Tanveer Rab et al. JCIN 2017;10:
Presentation transcript:

SKS Technique Clinical Case From Sharma SK, Sweeney J, Kini AS. Coronary Bifurcation Lesions: A Current Update. Cardiol Clin 2010;28:55–70. 1

Clinical Case: SKS Technique for LAD/D1 54 yrs old, with angina pectoris, coronary ASC of native vessel, positive CTA Medical history: HTN, Hyperlipidemia, H/o prior MI, s/p BMS dLAD 10/07 Medication: Carvedilol, Plavix, ASA, Lisinopril, Lipitor, Zoloft SKS technique for mid LAD/D1 bifurcation DES in mid-LAD DES in LAD-D1 From Sharma SK, Sweeney J, Kini AS. Coronary Bifurcation Lesions: A Current Update. Cardiol Clin 2010;28:55–70. 2

Clinical Case: SKS Technique for LAD/D1 70-80% stenosis mid-LAD 70-80% stenosis in LAD-D1 bifurcation PCI Technique: 7Fr FCL 4.0 Mach1 guide into the lesion From Sharma SK, Sweeney J, Kini AS. Coronary Bifurcation Lesions: A Current Update. Cardiol Clin 2010;28:55–70 3

Clinical Case: SKS Technique for LAD/D1 mid-LAD wired by Fielder and D1 wired by RunThrough and Fielder 1.5/6mm Sprinter balloon for mid-LAD lesions at 1 atm 2.5/6mm Flextome cutting balloon at 10 atm in D1 lesion From Sharma SK, Sweeney J, Kini AS. Coronary Bifurcation Lesions: A Current Update. Cardiol Clin 2010;28:55–70 4

Clinical Case: SKS Technique for LAD/D1 mid-LAD wired by Fielder and D1 wired by RunThrough and Fielder 1.5/6mm Sprinter balloon for mid-LAD lesions at 1 atm 2.5/6mm Flextome cutting balloon at 10 atm in D1 lesion From Sharma SK, Sweeney J, Kini AS. Coronary Bifurcation Lesions: A Current Update. Cardiol Clin 2010;28:55–70 5

Clinical Case: SKS Technique for LAD/D1 SKS technique for mid-LAD/D1 bifurcation: 3.00/13 mm Cypher in mid-LAD and 2.5/18mm Cypher in D1 6

Clinical Case: SKS Technique for LAD/D1 SKS technique for mid-LAD/D1 bifurcation: 3.00/13 mm Cypher in mid-LAD and 2.5/18mm Cypher in D1 -Both inflated simultaneously at 10 atm for 10 seconds 7

Clinical Case: SKS Technique for LAD/D1 SKS technique for prox-LAD/D1 bifurcation: 3.00/13 mm Cypher in mid-LAD and 2.5/18mm Cypher in D1 Both inflated simultaneously at 10 atm for 10 seconds Both deflate and LAD stent inflated at 20 atm for 10 seconds 8

Clinical Case: SKS Technique for LAD/D1 SKS technique for mid-LAD/D1 bifurcation: 3.00/13 mm Cypher in mid-LAD and 2.5/18mm Cypher in D1 Both inflated simultaneously at 10atm for 10 seconds Both deflate and LAD stent inflated at 20 atm for 10 seconds Deflate LAD stent and inflate D1 stent at 18atm for 10 seconds 9

Clinical Case: SKS Technique for LAD/D1 SKS technique for mid-LAD/D1 bifurcation: 3.00/13 mm Cypher in mid-LAD and 2.5/18mm Cypher in D1 Both inflated simultaneously at 10atm for 10 seconds Both deflate and LAD stent inflated at 20 atm for 10 seconds Deflate LAD stent and inflate D1 stent at 18atm for 10 seconds Both again inflated simultaneously at 10 atm for 10 seconds 10

Clinical Case: SKS Technique for LAD/D1 Final Results Post SKS technique for mid-LAD/D1 bifurcation stents after plaque modifications of D1 by CB 11

Clinical Case: SKS Technique for LAD/D1 Final Results Post SKS technique for mid-LAD/D1 bifurcation stents after plaque modifications of D1 by CB 12

Bifurcation lesion involving LAD and D1 SKS Technique Bifurcation lesion involving LAD and D1

PRECISE-SKS Pilot Study Duke’s Type D Bifurcation Lesion Conventional Technique (n=49): One stent in the main vessel & provisional stent in the side-branch SKS Technique (n=51): Simultaneous kissing stent deployment in the main vessel & side-branch Primary endpoint: angiographic restenosis at 8-9 months Secondary endpoints:30-day clinical MACE 9-month TLR 1-year freedom from MACE IVUS sub study of 20 pts in each arm 1-year clinical follow-up: death, TVR, MI